Literature DB >> 33330972

Clinical & Experimental Immunology: Highlights of 2020.

L S Taams1, R S Taylor2.   

Abstract

Entities:  

Mesh：

Year:  2021        PMID： 33330972      PMCID： PMC7744490          DOI： 10.1111/cei.13557

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN： 0009-9104            Impact factor:   4.330


× No keyword cloud information.
  14 in total

Review 1.  Mechanisms of checkpoint inhibition-induced adverse events.

Authors:  P Urwyler; I Earnshaw; M Bermudez; E Perucha; W Wu; S Ryan; L Mcdonald; S N Karagiannis; L S Taams; N Powell; A Cope; S Papa
Journal:  Clin Exp Immunol       Date:  2020-02-21       Impact factor: 4.330

2.  Late diagnosis of chronic granulomatous disease.

Authors:  T Barkai; R Somech; A Broides; R Gavrieli; B Wolach; N Marcus; D Hagin; T Stauber
Journal:  Clin Exp Immunol       Date:  2020-07-13       Impact factor: 4.330

Review 3.  VISTA: Coming of age as a multi-lineage immune checkpoint.

Authors:  M A ElTanbouly; E Schaafsma; R J Noelle; J L Lines
Journal:  Clin Exp Immunol       Date:  2020-02-04       Impact factor: 4.330

4.  Exogenous interleukin-2 can rescue in-vitro T cell activation and proliferation in patients with a novel capping protein regulator and myosin 1 linker 2 mutation.

Authors:  O Toker; M Berger; O Shamriz; A J Simon; A Lev; O Megged; O Ledder; E Picard; L Joseph; V Molho-Pessach; Y Tal; P Millman; M Slae; R Somech
Journal:  Clin Exp Immunol       Date:  2020-04-18       Impact factor: 4.330

5.  Pathological role of excessive DNA as a trigger of keratinocyte proliferation in psoriasis.

Authors:  Y Luo; T Hara; A Kawashima; Y Ishido; S Suzuki; N Ishii; T Kambara; K Suzuki
Journal:  Clin Exp Immunol       Date:  2020-06-08       Impact factor: 4.330

6.  MOSPD2 is a therapeutic target for the treatment of CNS inflammation.

Authors:  N Yacov; P Kafri; Y Salem; O Propheta-Meiran; B Feldman; E Breitbart; I Mendel
Journal:  Clin Exp Immunol       Date:  2020-05-18       Impact factor: 4.330

7.  British Society for Immunology/United Kingdom Primary Immunodeficiency Network consensus statement on managing non-infectious complications of common variable immunodeficiency disorders.

Authors:  C Bethune; W Egner; T Garcez; A Huissoon; S Jolles; Y Karim; R Jain; S Savic; K Kelley; D Grosse-Kreul; S Grigoriadou
Journal:  Clin Exp Immunol       Date:  2019-03-07       Impact factor: 4.330

8.  Using IL-2R/lymphocytes for predicting the clinical progression of patients with COVID-19.

Authors:  H Hou; B Zhang; H Huang; Y Luo; S Wu; G Tang; W Liu; L Mao; L Mao; F Wang; Z Sun
Journal:  Clin Exp Immunol       Date:  2020-05-15       Impact factor: 4.330

9.  A year in our understanding of COVID-19.

Authors:  R S Thwaites
Journal:  Clin Exp Immunol       Date:  2020-11       Impact factor: 4.330

Review 10.  Novel insights into dendritic cells in the pathogenesis of systemic sclerosis.

Authors:  T Carvalheiro; M Zimmermann; T R D J Radstake; W Marut
Journal:  Clin Exp Immunol       Date:  2020-02-13       Impact factor: 4.330
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.